Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > BUSINESS
BUSINESS
- CareNet, EP-PharmaLine to Jointly Provide Online, Phone Detailing Services
December 8, 2014
- Nipro Sets Up New Sales Firm in Malaysia
December 8, 2014
- Nippon Chemiphar to Set Up Plant in Vietnam, Operation Launch Slated in 2018
December 5, 2014
- First-Line Xalkori Shows Superiority to Chemotherapy in ALK-Positive NSCLC: Pfizer
December 5, 2014
- Chiome Bioscience Succeeds in Producing Antibody to Ebola
December 5, 2014
- Asahi Kasei Pharma Licenses Teribone to South Korea’s Dong-A ST
December 5, 2014
- M3 Poised to More than Double Revenue from Clinical Trial Services
December 5, 2014
- Safety Confirmed in Preliminary Results from PI Study of Preventive AIDS Vaccine: Dnavec
December 4, 2014
- Astellas, Janssen to End JAK Inhibitor Licensing Agreement
December 3, 2014
- Nippon Shinyaku’s Selexipag Filed for European Approval
December 3, 2014
- Otsuka to Buy US Firm Avanir Pharmaceuticals to Fully Enter Neurology Market
December 3, 2014
- Takata Seiyaku Obtains Marketing Authorization Rights for Antihistamine Polaramine from MSD
December 3, 2014
- Kowa Launches Glanatec for Treatment of Glaucoma and Ocular Hypertension
December 3, 2014
- Xtandi Approved for Chemotherapy-Naïve Patients in Europe: Astellas
December 3, 2014
- Takeda’s Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by US FDA
December 3, 2014
- A-zas Looks to Offer E-Detailing App, Big-Data Analyses to More Firms
December 2, 2014
- Pralia Captures Top Spot in GP Market in October “Mind Share” Ranking
December 2, 2014
- Eisai Upgrades China to Independent Region with New Holding Firm
December 2, 2014
- Ferring to Launch Japan’s 1st Progestational Hormone Agent in ART Program on Dec. 5
December 2, 2014
- Eisai Files Lenvatinib for Approval in South Korea
December 2, 2014
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…